[{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT05-01 Phase II adult clinical trials,,"},{"Key":"Keywords","Value":"Pancreatic cancer,Immune checkpoint blockade,Tumor microenvironment,Histone deacetylase inhibitor,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>M. Baretti<\/b><sup>1<\/sup>, L. Danilova<sup>1<\/sup>, J. N. Durham<sup>1<\/sup>, C. B. Betts<sup>2<\/sup>, L. Cope<sup>1<\/sup>, D. N. Sidiropoulos<sup>1<\/sup>, J. A. Tandurella<sup>1<\/sup>, S. Charmsaz<sup>1<\/sup>, N. Gross<sup>1<\/sup>, A. Hernandez<sup>1<\/sup>, W. J. HO<sup>1<\/sup>, C. Thoburn<sup>1<\/sup>, R. Walker<sup>1<\/sup>, J. Leatherman<sup>1<\/sup>, S. Mitchell<sup>1<\/sup>, B. Christmas<sup>1<\/sup>, D. A. Gaykalova<sup>1<\/sup>, S. Yegnasubramanian<sup>1<\/sup>, E. J. Fertig<sup>1<\/sup>, L. M. Coussens<sup>2<\/sup>, M. Yarchoan<sup>1<\/sup>, E. Jaffee<sup>1<\/sup>, N. S. Azad<sup>1<\/sup>; <br\/><sup>1<\/sup>Johns Hopkins University School of Medicine, Baltimore, MD, <sup>2<\/sup>Department of Cell, Developmental & Cancer Biology and Knight Cancer Institute, Oregon Health & Science University, Portland, OR","CSlideId":"","ControlKey":"a5575cbc-d210-4a4d-aea7-3488fdb06b64","ControlNumber":"9783","DisclosureBlock":"<b>&nbsp;M. Baretti, <\/b> <br><b>Incyte<\/b> Other, Advisory Board. <br><b>Astrazeneca<\/b> Other, Advisory Board. <br><b>Eisai<\/b> Other, Advisory Board.<br><b>L. Danilova, <\/b> None..<br><b>J. N. Durham, <\/b> None.&nbsp;<br><b>C. B. Betts, <\/b> <br><b>Akoya Biosciences<\/b> Employment.<br><b>L. Cope, <\/b> None..<br><b>D. N. Sidiropoulos, <\/b> None..<br><b>J. A. Tandurella, <\/b> None..<br><b>S. Charmsaz, <\/b> None..<br><b>N. Gross, <\/b> None..<br><b>A. Hernandez, <\/b> None..<br><b>W. J. Ho, <\/b> None..<br><b>C. Thoburn, <\/b> None..<br><b>R. Walker, <\/b> None..<br><b>J. Leatherman, <\/b> None..<br><b>S. Mitchell, <\/b> None..<br><b>B. Christmas, <\/b> None..<br><b>D. A. Gaykalova, <\/b> None..<br><b>S. Yegnasubramanian, <\/b> None..<br><b>E. J. Fertig, <\/b> None..<br><b>L. M. Coussens, <\/b> None..<br><b>M. Yarchoan, <\/b> None..<br><b>E. Jaffee, <\/b> None..<br><b>N. S. Azad, <\/b> None.","End":"4\/9\/2024 10:30:00 AM","HasWebcast":null,"Highlights":[],"Id":"11431","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"1","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT016","PresenterBiography":null,"PresenterDisplayName":"Marina Baretti, MD","PresenterKey":"433d2144-e643-4ba1-b640-d64e505acd98","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT016. Immunomodulation of the tumor microenvironment of pancreatic ductal adenocarcinoma with histone deacetylase inhibition: Results of a phase 2 clinical trial of entinostat in combination with nivolumab","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024 10:15AM","SessionId":"662","SessionOnDemand":"False","SessionTitle":"Biomarkers: Quantifying Pharmacodynamic Modulation","ShowChatLink":"false","Start":"4\/9\/2024 10:15:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Immunomodulation of the tumor microenvironment of pancreatic ductal adenocarcinoma with histone deacetylase inhibition: Results of a phase 2 clinical trial of entinostat in combination with nivolumab","Topics":null,"cSlideId":""},{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Other","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":". ","CSlideId":"","ControlKey":"c3cbc586-c99a-4226-a39c-bffd3cb23a14","ControlNumber":"12140","DisclosureBlock":"","End":"4\/9\/2024 10:45:00 AM","HasWebcast":null,"Highlights":[],"Id":"11839","IsPresentation":"False","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"2","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":null,"PresenterKey":null,"PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"Discussion","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024 10:15AM","SessionId":"662","SessionOnDemand":"False","SessionTitle":"Biomarkers: Quantifying Pharmacodynamic Modulation","ShowChatLink":"false","Start":"4\/9\/2024 10:30:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Discussion","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT06-01 Phase III adult clinical trials,,"},{"Key":"Keywords","Value":"Circulating tumor DNA,Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI),NSCLC,Osimertinib,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>P. A. Jänne<\/b><sup>1<\/sup>, K. Kobayashi<sup>2<\/sup>, J. Robichaux<sup>3<\/sup>, C. Lee<sup>4<\/sup>, S. Sugawara<sup>5<\/sup>, T.-Y. Yang<sup>6<\/sup>, T. Kim<sup>7<\/sup>, N. Yanagitani<sup>8<\/sup>, S.-W. Kim<sup>9<\/sup>, A. Markovets<sup>10<\/sup>, P. Bhetariya<sup>10<\/sup>, L. Poole<sup>11<\/sup>, D. Ghiorghiu<sup>12<\/sup>, R. Hartmaier<sup>3<\/sup>, J.-H. Yang<sup>13<\/sup>, D. Planchard<sup>14<\/sup>; <br\/><sup>1<\/sup>Department of Medical Oncology, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, <sup>2<\/sup>Department of Respiratory Medicine, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan, <sup>3<\/sup>Translational Medicine, Oncology R&D, AstraZeneca, Boston, MA, <sup>4<\/sup>Department of Medical Oncology, Cancer Care Centre, St. George Hospital, Kogarah, Australia, <sup>5<\/sup>Department of Pulmonary Medicine, Sendai Kousei Hospital, Hirosemachi, Aoba-ku, Sendai City, Miyagi Prefecture, Japan, <sup>6<\/sup>Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan, <sup>7<\/sup>Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of, <sup>8<\/sup>Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan, <sup>9<\/sup>Department of Oncology, Asan Medical Center, Seoul, Korea, Republic of, <sup>10<\/sup>Oncology Data Science, Research and Early Development, Oncology R&D, AstraZeneca, Boston, MA, <sup>11<\/sup>Oncology Biometrics, AstraZeneca, Cambridge, United Kingdom, <sup>12<\/sup>Late Development Oncology, AstraZeneca, Baar, Switzerland, <sup>13<\/sup>Department of Oncology, National Taiwan University Hospital and Graduate Institute of Oncology, National Taiwan University, Taipei, Taiwan, <sup>14<\/sup>Department of Medical Oncology, Thoracic Group, Institut Gustave Roussy, Villejuif, France and Faculty of Medicine, Paris-Saclay University, Paris, France","CSlideId":"","ControlKey":"54a7e3e6-5f24-4a75-af0c-9a0584ebb537","ControlNumber":"9532","DisclosureBlock":"<b>&nbsp;P. A. Jänne, <\/b> <br><b>Astellas Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Dachii-Sankyo, Eli Lilly, PUMA, Takeda<\/b> Grant\/Contract. <br><b>AbbVie, AstraZeneca, Biocartis, Boehringer Ingelheim, Chugai Pharmaceuticals Co., Ltd., Daiichi-Sankyo, Duality Biologics, Eli Lilly, Frontier Medicines, Hongyun Biotechnology, Ignyta, LOXO Oncology<\/b> Other, Advisory board. <br><b>Merus, Mirati Therapeutics Inc., Monte Rosa, Novartis, Pfizer, PUMA, Roche \/ Genentech, Sanofi, Scorpion Therapeutics, SFJ Pharmaceuticals, Silicon Therapeutics, Takeda, Transcenta, Voronoi<\/b> Other, Advisory board. <br><b>Allorion Therapeutics, Accutar Biotech, AbbVie, Monte Rosa, Scorpion Therapeutics, Merus, Frontier Medicines, Hongyun Biotechnology, Duality Biologics, Blueprint Medicines<\/b> Other, Advisory board. <br><b>Lab corp<\/b> Other, Co-inventor on a DFCI patent licensed to Lab Corp.\u000d\u000aRoyalties: DCFI owned IP licensed to Lap Corp..<br><b>K. Kobayashi, <\/b> None.&nbsp;<br><b>J. Robichaux, <\/b> <br><b>AstraZeneca<\/b> Employment, Stock. <br><b>UT MD Anderson Cancer Center<\/b> Other, UT MD Anderson Cancer Center and Spectrum Pharmaceuticals: Inventor on patents held by UT MD Anderson Cancer Center licenced to SP for treatment of EGFR\/HER2 exon 20 mutant cancers\u000d\u000a\u000d\u000aUT MD Anderson Cancer Center: Inventor on patent held by UT MDACC regarding EGFR mutation subtypes and methods of treatment (no monetary exchange)\u000d\u000a. <br><b>C. Lee, <\/b> <br><b>AstraZeneca, Roche, Merck KGA, Amgen, Norvatis<\/b> Grant\/Contract. <br><b>AstraZeneca<\/b> Travel. <br><b>Amgen, AstraZeneca, Daiichi Sankyo, GlaxoSmithKline, Janssen Oncology, Merck KGaA , MSD Oncology, Novartis, Pfizer, Roche, Takeda<\/b> Other, Advisory board. <br><b>S. Sugawara, <\/b> <br><b>AnHeart, AstraZeneca, Bristol Myers Squibb, Chugai Pharmaceutical Co., Ltd., Dachii-Sankyo, Merck Sharp & Dohme K.K., Nippon Boehringer Ingelheim., Ono Pharmaceutical Co., Ltd.<\/b> Other, Local PI. <br><b>AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Chugai Pharmaceutical Co., Ltd., Kyowa Kirin, Lilly, Merck, Merck Sharp & Dohme K.K., Nippon Boehringer Ingelheim, Nippon Kayaku, Novartis<\/b> Other, Speakers bureau. <br><b>Ono Pharmaceutical Co., Ltd., Otsuka, Pfizer, Taiho Pharmaceutical Co., Ltd., Takeda, Thermo Fisher Scientific, TOWA Pharmaceutical<\/b> Other, Speakers bureau.<br><b>T. Yang, <\/b> None.&nbsp;<br><b>T. Kim, <\/b> <br><b>Amgen, AstraZeneca, Amgen, AstraZeneca\/MedImmune, Boryung, Daiichi-Sankyo, HK inno.N, IMBDx. Inc., Janssen, Novartis, Regeneron, Roche\/Genentech, Samsung Bioepis, Takeda, and Yuhan<\/b> Consulting\/advisory roles. <br><b>N. Yanagitani, <\/b> <br><b>Pfizer<\/b> Other, Advisory board. <br><b>Chugai Pharmaceutical Co., Ltd.<\/b> Other, Consultant. <br><b>Bayer AG, Boehringer Ingelheim, Bristol Myers Squibb, Chugai Pharmaceutical Co., Ltd., Eli Lilly, Merck Sharp & Dohme, Novartis, Ono Pharma UK Ltd., Pfizer, Taiho Pharmaceutical Co., Ltd.<\/b> Other, Lecture fees. <br><b>S. Kim, <\/b> <br><b>Yuhan<\/b> Grant\/Contract. <br><b>A. Markovets, <\/b> <br><b>AstraZeneca<\/b> Employment, Stock. <br><b>P. Bhetariya, <\/b> <br><b>AstraZeneca<\/b> Employment, Stock. <br><b>L. Poole, <\/b> <br><b>AstraZeneca<\/b> Employment, Stock. <br><b>Lily, Takeda<\/b> Stock. <br><b>D. Ghiorghiu, <\/b> <br><b>AstraZeneca<\/b> Employment. <br><b>R. Hartmaier, <\/b> <br><b>AstraZeneca<\/b> Employment, Stock. <br><b>US11066709B2<\/b> Patent, Inventor on patent US11066709B2 (no fees or royalties). <br><b>J. Yang, <\/b> <br><b>AstraZeneca<\/b> Grant\/Contract, Other, Research funding\u000d\u000aAdvisory board\u000d\u000aCoordinating PI\u000d\u000aSteering committee member. <br><b>Dizal Pharmaceutical<\/b> Other, Advisory board\u000d\u000aCoordinating PI\u000d\u000aSteering committee member. <br><b>Merck Sharp & Dohme<\/b> Other, Advisory board\u000d\u000aCoordinating PI. <br><b>Eli Lilly<\/b> Other, Advisory board\u000d\u000aSteering committee member. <br><b>Janssen<\/b> Other, Advisory board\u000d\u000aSteering committee member. <br><b>Takeda<\/b> Advisory board\u000d\u000aSteering committee member. <br><b>Yuhan<\/b> Other, Advisory board\u000d\u000aSteering committee member. <br><b>ASCO, ESMO, IASLC<\/b> Other, Member. <br><b>Amgen, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Gilead, GlaxoSmithKline, Regeneron, Merck KGaA, Novartis, Pfizer, Roche \/ Genentech<\/b> Other, Advisory board. <br><b>D. Planchard, <\/b> <br><b>AstraZeneca<\/b> Other, Advisory board\u000d\u000aCoordinating PI\u000d\u000aSpeaker, consultant, advisor. <br><b>AbbVie<\/b> Other, Advisory board\u000d\u000aCoordinating PI\u000d\u000aSpeaker, consultant, advisor. <br><b>Bristol-Myers Squibb<\/b> Other, Advisory board\u000d\u000aCoordinating PI\u000d\u000aSpeaker, consultant, advisor. <br><b>Celgene<\/b> Other, Advisory board\u000d\u000aSpeaker, consultant, advisor. <br><b>Daiichi Sankyo<\/b> Other, Advisory board\u000d\u000aCoordinating PI\u000d\u000aSpeaker, consultant, advisor. <br><b>Merck<\/b> Other, Advisory board\u000d\u000aCoordinating PI\u000d\u000aSpeaker, consultant, advisor. <br><b>Novartis<\/b> Other, Advisory board\u000d\u000aCoordinating PI\u000d\u000aSpeaker, consultant, advisor. <br><b>Janssen<\/b> Other, Advisory board\u000d\u000aCoordinating PI\u000d\u000aSpeaker, consultant, advisor. <br><b>Pfizer<\/b> Other, Advisory board\u000d\u000aCoordinating PI\u000d\u000aSpeaker, consultant, advisor. <br><b>Roche<\/b> Other, Advisory board\u000d\u000aCoordinating PI\u000d\u000aSpeaker, consultant, advisor. <br><b>Pierre-fabre<\/b> Other, Advisory board\u000d\u000aCoordinating PI\u000d\u000aSpeaker, consultant, advisor. <br><b>Takeda<\/b> Other, Advisory board\u000d\u000aCoordinating PI\u000d\u000aSpeaker, consultant, advisor. <br><b>ArriVent<\/b> Other, Advisory board\u000d\u000aCoordinating PI\u000d\u000aSpeaker, consultant, advisor. <br><b>Mirati<\/b> Other, Advisory board\u000d\u000aCoordinating PI\u000d\u000aSpeaker, consultant, advisor. <br><b>Seagen<\/b> Other, Advisory board\u000d\u000aCoordinating PI\u000d\u000aSpeaker, consultant, advisor. <br><b>Boehringer Ingelheim<\/b> Other, Coordinating PI\u000d\u000aSpeaker, consultant, advisor. <br><b>Eli Lilly<\/b> Other, Coordinating PI\u000d\u000aSpeaker, consultant, advisor. <br><b>MedImmune, Sanofi-Aventis, Taiho Pharma, Novocure<\/b> Other, Coordinating PI.","End":"4\/9\/2024 11:00:00 AM","HasWebcast":null,"Highlights":[],"Id":"11432","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"3","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT017","PresenterBiography":null,"PresenterDisplayName":"Pasi Jänne, MD;PhD","PresenterKey":"6cd58854-1ca3-4df1-81de-3d276861baeb","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT017. FLAURA2: exploratory analysis of baseline (BL) and on-treatment plasma EGFRm dynamics in patients (pts) with EGFRm advanced NSCLC treated with first-line (1L) osimertinib (osi) &#177; platinum-pemetrexed","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024 10:15AM","SessionId":"662","SessionOnDemand":"False","SessionTitle":"Biomarkers: Quantifying Pharmacodynamic Modulation","ShowChatLink":"false","Start":"4\/9\/2024 10:45:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"FLAURA2: exploratory analysis of baseline (BL) and on-treatment plasma EGFRm dynamics in patients (pts) with EGFRm advanced NSCLC treated with first-line (1L) osimertinib (osi) &#177; platinum-pemetrexed","Topics":null,"cSlideId":""},{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Other","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":". ","CSlideId":"","ControlKey":"75de1d25-6b26-4167-aeef-82fec930706e","ControlNumber":"12141","DisclosureBlock":"","End":"4\/9\/2024 11:15:00 AM","HasWebcast":null,"Highlights":[],"Id":"11840","IsPresentation":"False","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"4","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":null,"PresenterKey":null,"PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"Discussion","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024 10:15AM","SessionId":"662","SessionOnDemand":"False","SessionTitle":"Biomarkers: Quantifying Pharmacodynamic Modulation","ShowChatLink":"false","Start":"4\/9\/2024 11:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Discussion","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT06-01 Phase III adult clinical trials,,"},{"Key":"Keywords","Value":"PARP inhibitors,Prostate cancer,Cancer genetics,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>J. M. Piulats<\/b><sup>1<\/sup>, A. A. Azad<sup>2<\/sup>, A. Laird<sup>3<\/sup>, N. Matsubara<sup>4<\/sup>, K. Fizazi<sup>5<\/sup>, N. D. Shore<sup>6<\/sup>, L. Karsh<sup>7<\/sup>, G. Liu<sup>8<\/sup>, A. P. Fay<sup>9<\/sup>, J. Carles<sup>10<\/sup>, R. J. Jones<sup>11<\/sup>, E. Voog<sup>12<\/sup>, S. Zschäbitz<sup>13<\/sup>, U. De Giorgi<sup>14<\/sup>, S. M. Yip<sup>15<\/sup>, X. Mu<sup>3<\/sup>, X. Lin<sup>3<\/sup>, A. Engelsberg<sup>16<\/sup>, N. Agarwal<sup>17<\/sup>; <br\/><sup>1<\/sup>Institut Català d’Oncologia–Bellvitge Institute for Biomedical Research, Barcelona, Spain, <sup>2<\/sup>Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia, <sup>3<\/sup>Pfizer Inc., La Jolla, CA, <sup>4<\/sup>National Cancer Center Hospital East, Chiba, Japan, <sup>5<\/sup>Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France, <sup>6<\/sup>Carolina Urologic Research Center, Myrtle Beach, SC, <sup>7<\/sup>The Urology Center of Colorado, Denver, CO, <sup>8<\/sup>Carbone Cancer Center, University of Wisconsin- Madison, Madison, WI, <sup>9<\/sup>PUCRS School of Medicine, Porto Alegre, Brazil, <sup>10<\/sup>Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, <sup>11<\/sup>School of Cancer Sciences, University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom, <sup>12<\/sup>Clinique Victor Hugo Centre Jean Bernard, Le Mans, France, <sup>13<\/sup>National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany, <sup>14<\/sup>IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Meldola, Italy, <sup>15<\/sup>Tom Baker Cancer Centre and Cumming School of Medicine, Calgary, AB, Canada, <sup>16<\/sup>Pfizer Pharma GmbH, Berlin, Germany, <sup>17<\/sup>Huntsman Cancer Institute (NCI-CCC), University of Utah, Salt Lake City, UT","CSlideId":"","ControlKey":"80192f1a-922b-4b45-adc3-a0590aaff588","ControlNumber":"10251","DisclosureBlock":"<b>&nbsp;J. M. Piulats, <\/b> <br><b>Advanced Accelerator Applications\/Novartis; Astellas Pharma; AstraZeneca; Bayer; BeiGene; Bristol Myers Squibb; Clovis; Janssen; MSD Oncology; Pfizer; Roche; Sanofi<\/b> Other, consulting or advisory role. <br><b>BeiGene; BMS; Janssen; Merck Serono; Mirati; MSD; Pfizer<\/b> Other, research funding. <br><b>AstraZeneca; Pfizer<\/b> Travel. <br><b>A. A. Azad, <\/b> <br><b>Aculeus Therapeutics; Amgen; Astellas Pharma; AstraZeneca, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Ipsen; Janssen; Merck Serono; Merck Sharp & Dohme; Novartis, Noxopharm; Pfizer; Sanofi<\/b> Other, honoraria. <br><b>Telix Pharmaceuticals; Tolmar<\/b> Other, honoraria. <br><b>Amgen; Arvinas; Astellas Pharma; AstraZeneca; Bayer; Bristol Myers Squibb; Daiichi Sankyo; Ipsen; Janssen; Merck Serono; Merck Sharp & Dohme; Novartis; Noxopharm; Pfizer; Sanofi; Telix; Tolmar<\/b> Other, participation on advisory boards. <br><b>OncoSec<\/b> Other, participation on a data safety monitoring board. <br><b>Aptevo Therapeutics; Astellas Pharma; AstraZeneca; Bionomics; Bristol Myers Squibb; Exelixis; Gilead Sciences; GlaxoSmithKline; Hinova Pharmaceuticals; Ipsen; Janssen; Lilly; MedImmune; Merck Serono<\/b> Other, research funding. <br><b>MSD; Novartis; Pfizer; Sanofi; Synthorx<\/b> Other, research funding. <br><b>Amgen; Astellas Pharma; Janssen; Merck Serono; Novartis; Pfizer; Tolmar<\/b> Travel. <br><b>Astellas Pharma; Exelixis; Pfizer<\/b> Other, receiving medical writing services. <br><b>the Clinical Oncology Society of Australia<\/b> Other, Chair of the Urologic Oncology Group. <br><b>ANZUP Cancer Trials Group<\/b> Other, Chair of the Translational Research Subcommittee and on the Scientific Advisory Committee. <br><b>Aculeus Therapeutics; Astellas Pharma; Janssen; Novartis<\/b> Other, consulting fees. <br><b>A. Laird, <\/b> <br><b>Pfizer<\/b> Employment, Stock. <br><b>N. Matsubara, <\/b> <br><b>Sanofi<\/b> Other, honoraria (personal). <br><b>Amgen; Astellas Pharma; AstraZeneca; Bayer; Chugai Pharma; Eisai; Janssen; Lilly; MSD; Pfizer; PRA Health Science; Roche; Seagen; Taiho; Takeda<\/b> Other, research funding (institution). <br><b>Pfizer<\/b> Travel. <br><b>K. Fizazi, <\/b> <br><b>Advanced Accelerator Applications\/Novartis; Amgen; Astellas Pharma; AstraZeneca; Bayer; Clovis Oncology; Daiichi Sankyo; Janssen; MSD; Novartis; Pfizer; Sanofi<\/b> Other, honoraria (institution) for participation in advisory boards and talks. <br><b>Arvinas; CureVac; MacroGenics; Orion<\/b> Other, honoraria (personal) for participation in advisory boards. <br><b>N. D. Shore, <\/b> <br><b>AbbVie; Alessa Therapeutics; Akido; Amgen; Arquer; Asieris; Astellas Pharma; AstraZeneca; Bayer; Boston Scientific; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals; Clovis Oncology<\/b> Other, consulting or advisory role. <br><b>Dendreon; Exact Imaging; Exact Sciences; FerGene; Ferring; FIZE Medical; Foundation Medicine; GenesisCare; Genentech; Guardant Health; ImmunityBio; Incyte; Invitae; Janssen; Lantheus; Lilly<\/b> Other, consulting or advisory role. <br><b>Mdxhealth; Merck; Minomic; Myovant Sciences; Myriad Genetics; Nymox; Pacific Edge Biotechnology; Pfizer; Photocure; PlatformQ; Profound; Promaxo; Propella Therapeutics; Protara<\/b> Other, consulting or advisory role. <br><b>Sanofi; Sesen Bio; Speciality Networks; Telix Pharmaceuticals; Tolmar; UroGen Pharma; Vaxiion; Vessi<\/b> Other, consulting or advisory role. <br><b>Ferring<\/b> Other, providing expert testimony. <br><b>Photocure<\/b> Other, leadership or other fiduciary role in other board, society, committee, or advocacy group. <br><b>L. Karsh, <\/b> <br><b>Swan Valley Medical<\/b> Stock. <br><b>Astellas; AstraZeneca; Bayer; Dendreon; Janssen; Merck; Pfizer; Sanofi<\/b> Other, consulting or advisory role. <br><b>Astellas; AstraZeneca; Bayer; Dendreon; Janssen; Lantheus; Merck; Pfizer<\/b> Other, Speakers’ bureau role. <br><b>Astellas; Bayer; BMS; Dendreon; FKD; Janssen; KDx; Myovant; Neuspera; OncoCell; Pfizer; Tavanta<\/b> Other, Research funding to his institution.<br><b>G. Liu, <\/b> None.&nbsp;<br><b>A. P. Fay, <\/b> <br><b>Astellas Pharma; AstraZeneca; Bristol Myers Squibb; Ipsen; Janssen; MSD; Novartis; Pfizer; Roche<\/b> Other, honoraria. <br><b>Bayer; Ipsen; Janssen; MSD; Novartis; Pfizer; Roche<\/b> Other, consulting or advisory role. <br><b>Brazilian Information Oncology<\/b> Stock, Stock Option. <br><b>AstraZeneca; Bristol Myers Squibb; CAPES – CNPq; Foundation Medicine; Ipsen; MSD; Roche<\/b> Other, research funding. <br><b>Astellas Pharma; AstraZeneca; BMS; Ipsen; Janssen; MSD; Novartis; Pfizer; Roche<\/b> Travel. <br><b>J. Carles, <\/b> <br><b>Advanced Accelerator Applications\/Novartis; Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb; Johnson & Johnson; MSD Oncology; Pfizer; Roche; Sanofi<\/b> Other, consulting or advisory role. <br><b>Astellas Pharma; Bayer; Johnson & Johnson<\/b> Other, participation in speakers’ bureau. <br><b>AB Science; Aragon Pharmaceuticals; AROG Pharmaceuticals; Astellas Pharma; AstraZeneca AB; AVEO Pharmaceuticals; Bayer AG; Blueprint Medicines; BN ImmunoTherapeutics; Boehringer Ingelheim España SA<\/b> Other, research funding (institution). <br><b>Bristol Myers Squibb International Corporation; Clovis Oncology; Cougar Biotechnology; Deciphera; Exelixis; Genentech; GlaxoSmithKline; Incyte; Janssen-Cilag International NV; Karyopharm Therapeutics<\/b> Other, research funding (institution). <br><b>Laboratoires Leurquin Mediolanum; Lilly; MedImmune; Millennium Pharmaceuticals; Nanobiotix; Novartis Farmacéutica SA; Pfizer; Puma Biotechnology; Roche; Sanofi Aventis GmbH; SFJ Pharmaceuticals Group<\/b> Other, research funding (institution). <br><b>Teva<\/b> Other, research funding (institution). <br><b>AstraZeneca; BMS; Ipsen; Roche<\/b> Travel. <br><b>R. J. Jones, <\/b> <br><b>Astellas Pharma; Bayer; Bristol Myers Squibb; Ipsen; Janssen; Merck Serono; MSD; Pfizer; Roche<\/b> Other, honoraria. <br><b>Astellas Pharma; Bayer; Bristol Myers Squibb; Ipsen; Janssen; Merck Serono; MSD; Novartis; Pfizer; Roche<\/b> Other, consulting or advisory role. <br><b>Astellas Pharma; Bayer; Clovis Oncology; Exelixis; Roche<\/b> Other, research funding. <br><b>Bayer; Janssen<\/b> Travel.<br><b>E. Voog, <\/b> None.&nbsp;<br><b>S. Zschäbitz, <\/b> <br><b>Amgen; Astellas; Bayer; Bristol Myers Squibb; Merck Serono; Pfizer<\/b> Other, personal and institutional payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events. <br><b>Eisai; Janssen; Novartis<\/b> Other, personal payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events. <br><b>Amgen; Bayer; Merck Serono<\/b> Other, personal and institutional participation on a data safety monitoring board or advisory board. <br><b>Eisai; Gilead; Ipsen; Janssen; Novartis<\/b> Other, personal participation on a data safety monitoring board or advisory board. <br><b>Bristol Myers Squibb; MSD; Pfizer<\/b> Other, Institutional participation on a data safety monitoring board or advisory board. <br><b>Eisai<\/b> Other, Institutional research funding. <br><b>Amgen; Astellas Pharma; AstraZeneca; Bayer; Ipsen; Janssen; Merck Serono; MSD; Pfizer<\/b> Travel. <br><b>MSD<\/b> Other, institutional payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events. <br><b>U. De Giorgi, <\/b> <br><b>Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol Myers Squibb; Dompé Farmaceutici; Eisai; Ipsen; Janssen; Merck KGaA; MSD; Novartis; Pfizer<\/b> Other, consulting or advisory role. <br><b>AstraZeneca; Roche; Sanofi<\/b> Other, research funding (institution). <br><b>AstraZeneca; Ipsen; Pfizer<\/b> Travel. <br><b>S. M. Yip, <\/b> <br><b>Amgen; Astellas Pharma; AstraZeneca; Merck; Bayer; Bristol Myers Squibb; Novartis; Pfizer; Hoffman-La Roche; Ipsen; Janssen; OncoHelix<\/b> Other, consultancy or advisory role for and honoraria. <br><b>X. Mu, <\/b> <br><b>Pfizer Inc<\/b> Employment, Stock. <br><b>X. Lin, <\/b> <br><b>Pfizer<\/b> Employment, Stock. <br><b>A. Engelsberg, <\/b> <br><b>Pfizer<\/b> Employment, Stock. <br><b>N. Agarwal, <\/b> <br><b>Astellas Pharma; AstraZeneca; AVEO; Bayer; Bristol Myers Squibb; Calithera Biosciences; Eisai; EMD Serono; Exelixis; Foundation Medicine; Genentech; Gilead Sciences; Immunomedics; Janssen; Lilly<\/b> Other, honorarium for consultancy before May 2021. <br><b>MEI Pharma<\/b> Other, honorarium for consultancy before May 2021. <br><b>Arvinas; Astellas Pharma; AstraZeneca; Bayer; Bristol Myers Squibb; Calithera Biosciences; Celldex; Clovis Oncology; CRISPR Therapeutics; Eisai; EMD Serono; Exelixis; Genentech; Gilead Sciences<\/b> Other, research funding (institution). <br><b>GlaxoSmithKline; Immunomedics; Janssen; Lava; Lilly; Merck; Nektar; Neoleukin; Novartis; ORIC Pharmaceuticals; Pfizer; Rexahn; Roche; Sanofi; Seagen; Takeda; TRACON<\/b> Other, research funding (institution).","End":"4\/9\/2024 11:30:00 AM","HasWebcast":null,"Highlights":[],"Id":"11433","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"5","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT018","PresenterBiography":null,"PresenterDisplayName":"Josep Piulats, MD, PhD","PresenterKey":"c996ff71-d260-4610-b6e5-e58e6a9a1dd4","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT018. <i>TMPRSS2<\/i><i>-ERG<\/i> and <i>RB1<\/i> as candidate predictive biomarkers for efficacy in TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024 10:15AM","SessionId":"662","SessionOnDemand":"False","SessionTitle":"Biomarkers: Quantifying Pharmacodynamic Modulation","ShowChatLink":"false","Start":"4\/9\/2024 11:15:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"<i>TMPRSS2<\/i><i>-ERG<\/i> and <i>RB1<\/i> as candidate predictive biomarkers for efficacy in TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","Topics":null,"cSlideId":""},{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Other","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":". ","CSlideId":"","ControlKey":"5e9f7742-ee7e-4c9a-aa54-ca6bcb1afc33","ControlNumber":"12143","DisclosureBlock":"","End":"4\/9\/2024 11:45:00 AM","HasWebcast":null,"Highlights":[],"Id":"11842","IsPresentation":"False","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"6","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":null,"PresenterKey":null,"PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"Discussion","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024 10:15AM","SessionId":"662","SessionOnDemand":"False","SessionTitle":"Biomarkers: Quantifying Pharmacodynamic Modulation","ShowChatLink":"false","Start":"4\/9\/2024 11:30:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Discussion","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT05-01 Phase II adult clinical trials,,"},{"Key":"Keywords","Value":"Glioblastoma,Bortezomib,MGMT,Temozolomide,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>M. A. Rahman<\/b><sup>1<\/sup>, D. Goplen<sup>2<\/sup>, A. Waha<sup>3<\/sup>, L. Oltedal<sup>2<\/sup>, J. Haasz<sup>2<\/sup>, S. Kumar<sup>4<\/sup>, E. Birkeland<sup>1<\/sup>, H. Miletic<sup>2<\/sup>, F. Selheim<sup>1<\/sup>, M. Chekenya<sup>1<\/sup>; <br\/><sup>1<\/sup>University of Bergen, Bergen, Norway, <sup>2<\/sup>Haukeland University Hospital, Bergen, Norway, <sup>3<\/sup>University of Bonn, Bonn, Germany, <sup>4<\/sup>Memorial University of Newfoundland, Department of Ocean Sciences, St. John's, NL, Canada","CSlideId":"","ControlKey":"10a5feb2-c159-4f34-be45-813c0d1baf1d","ControlNumber":"10356","DisclosureBlock":"&nbsp;<b>M. A. Rahman, <\/b> None..<br><b>D. Goplen, <\/b> None..<br><b>A. Waha, <\/b> None..<br><b>L. Oltedal, <\/b> None..<br><b>J. Haasz, <\/b> None..<br><b>S. Kumar, <\/b> None..<br><b>E. Birkeland, <\/b> None..<br><b>H. Miletic, <\/b> None..<br><b>F. Selheim, <\/b> None..<br><b>M. Chekenya, <\/b> None.","End":"4\/9\/2024 12:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11434","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"7","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT019","PresenterBiography":null,"PresenterDisplayName":"Mohummad Rahman, PhD","PresenterKey":"db5f77fc-403e-490b-9c06-eb2a68fade51","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT019. Biological mechanisms underlying objective responses in recurrent GBM patients treated with sequential bortezomib and temozolomide: An interim analysis of NCT03643549 Phase IB\/II trial<b><\/b>","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024 10:15AM","SessionId":"662","SessionOnDemand":"False","SessionTitle":"Biomarkers: Quantifying Pharmacodynamic Modulation","ShowChatLink":"false","Start":"4\/9\/2024 11:45:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Biological mechanisms underlying objective responses in recurrent GBM patients treated with sequential bortezomib and temozolomide: An interim analysis of NCT03643549 Phase IB\/II trial<b><\/b>","Topics":null,"cSlideId":""},{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Other","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":". ","CSlideId":"","ControlKey":"9c8e961e-0310-4b52-b514-692c01e792e8","ControlNumber":"12144","DisclosureBlock":"","End":"4\/9\/2024 12:15:00 PM","HasWebcast":null,"Highlights":[],"Id":"11843","IsPresentation":"False","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"8","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":null,"PresenterKey":null,"PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"Discussion","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024 10:15AM","SessionId":"662","SessionOnDemand":"False","SessionTitle":"Biomarkers: Quantifying Pharmacodynamic Modulation","ShowChatLink":"false","Start":"4\/9\/2024 12:00:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Discussion","Topics":null,"cSlideId":""}]